Lepore D, et al. - A comparative scrutiny was performed of the structural outcome at age 4 years of eyes treated with intravitreal injection of bevacizumab, with fellow eyes treated with conventional laser photoablation in type 1 retinopathy of prematurity (ROP). Fluorescein angiography demonstrated potentially serious and long-term ocular effects. These occurred more commonly after bevacizumab therapy for acute-phase ROP than after laser.